樂觀
$27.96
情境價格
$24.500
+0.720 (+2.94%)收盤時
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.
Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Schrödinger Grants Restricted Stock Units to New Employees

Schrödinger to Report Q3 2026 Financial Results on November 4

New Study Reveals Multi-Lithium Ion Clustering in Battery Electrolytes

Schrodinger Inc Stock Surpasses Analyst Target Price

MindWalk Secures $30 Million Unsecured Credit Facility
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).
Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。